Platinum Investment Management Ltd. maintained its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,800 shares of the biopharmaceutical company’s stock at the end of the second quarter. Platinum Investment Management Ltd. owned about 0.07% of Agios Pharmaceuticals worth $1,841,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Swiss National Bank grew its holdings in shares of Agios Pharmaceuticals by 3.4% during the 1st quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock valued at $3,233,000 after acquiring an additional 1,800 shares in the last quarter. Spark Investment Management LLC grew its holdings in shares of Agios Pharmaceuticals by 139.9% during the 2nd quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after acquiring an additional 49,400 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 8.3% during the 1st quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after acquiring an additional 20,336 shares in the last quarter. Hood River Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 2.3% during the 2nd quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock valued at $6,115,000 after acquiring an additional 2,626 shares in the last quarter. Finally, TD Asset Management Inc. grew its holdings in shares of Agios Pharmaceuticals by 4.9% during the 2nd quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,544,000 after acquiring an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 0.52% on Friday, reaching $70.45. 284,949 shares of the company’s stock were exchanged. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $71.40. The firm’s 50-day moving average is $63.89 and its 200-day moving average is $56.11. The firm’s market cap is $3.41 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s revenue was up 62.1% on a year-over-year basis. During the same period last year, the business earned ($1.47) EPS. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $56.14, for a total transaction of $196,490.00. Following the completion of the sale, the director now owns 86,697 shares in the company, valued at approximately $4,867,169.58. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott Biller sold 10,470 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $70.00, for a total transaction of $732,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 228,408 shares of company stock valued at $14,976,478. 10.55% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Platinum Investment Management Ltd. Has $1,841,000 Stake in Agios Pharmaceuticals, Inc. (AGIO)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/08/platinum-investment-management-ltd-has-1841000-stake-in-agios-pharmaceuticals-inc-agio.html.

Several equities analysts have recently commented on AGIO shares. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, June 11th. Cann restated a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $75.20.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.